Roy Castle Lung Cancer Research Programme

2nd Dec 2021, 12:00pm - 1:30pm


Edge Hill University

The Roy Castle Lung Cancer Research Programme (RCLCRP) aims to reduce lung cancer mortality by enabling early diagnosis through developing and implementing a molecular-epidemiological risk assessment and biomarkers of pre-clinical carcinogenesis, used in conjunction with low-dose CT screening.

The two main branches of the RCLCRP are:

The Liverpool Lung Project (LLP), which collected data and tissue samples individuals at risk of lung cancer in the general population, from those undergoing diagnosis in hospitals and from those receiving treatment after diagnosis.

The UK Lung Cancer Screening trial (UKLS) – the only randomised control trial of low-dose CT in the UK.


This presentation will provide details on the development and current status of the projects, with emphasis on the research opportunities and challenges at present and in the future.

Programme : 12:00 – Twenty-two years LLP: Concept, Development & Opportunities, Professor John K Field, LLP Director

12:30 – LLP biobanking: Challenges and solutions, Dr Mike Davies, Clinical Resources Lead

12:45 – LLP Biomarkers: Prospects & limitations, Dr Lakis Liloglou, Biomarkers Lead

1:00 – Q&A and Networking

Venue: This event will take place on the Ormskirk campus, room will be provided once booked on the event. (Option available to join online)

To book your place please visit here 

Professor John Field, PhD, FRCPath has a Personal Clinical Chair in Molecular Oncology at the University of Liverpool. He is a Visiting Professor at University College London, holds the post of Director of Research of the Roy Castle Lung Cancer Research Programme. He is the Chief Investigator for the UK Lung Cancer Screening Trial (UKLS). Previous Chair of the IASLC Screening Prevention & Early Detection Committee and he formed IASLC Strategic Screening Advisory Group. Member of ILCCO and currently serving on the Steering Committee. He was presented with the IASLC Joseph Cullen Award at the WCLC 2011, in recognition of lifetime scientific achievements in lung cancer prevention research. He is Co-Chair of the IASLC Strategic Screening Advisory Committee and Co-lead on the IASLC Early Lung Cancer Imaging Confederation (ELIC) project.

He is the principal investigator of the Liverpool Lung Project, a molecular- epidemiological study into the early detection of lung cancer (~14,000 recruited), funded by the Roy Castle Lung Cancer Foundation. The UKLS and the LLP form part of the NCRI Lung Cancer portfolio. A Partner in the FP7 CURELUNG and LCAOS projects and co-applicant on the recently funded NIH U19 programme grant; also contributed to the lung cancer genetic susceptibility ‘Lung Oncoarray’ project. He is also heavily involved in the identification of molecular diagnostic markers in lung and head & neck cancers. His research funding has been provided mainly by the RCF, NWCRF, MRC, CRUK, EU, NIH and the HTA.


Professor Field is the author of over 315 international (peer reviewed) papers in his area of expertise with an h index of 67 and has given more than 350 presentations at medical and scientific conferences around the world.


Dr Mike Davies gained his BSc in Biochemistry from Kings College London (with a 1 year work placement at Smith, Kline & French Ltd., Welwyn) and his PhD from the University of Liverpool (as a Glaxo Research Studentship). The majority of his career as a researcher has been in the field of oncology, mostly breast cancer and lung cancer. Following a Glaxo sponsored post-doc at Liverpool, he spent 11 years working for Clatterbridge Cancer Research Trust, a small independent research charity associated with Clatterbridge Centre for Oncology. In 2007 he returned to the University of Liverpool and in 2011, secured his current position in the Roy Castle Lung Cancer Research Programme with Prof John Field and Dr Lakis Liloglou. Having participated in the EU FP7 CURELUNG & LCAOS research projects, he currently heads the Clinical Resources group and manages the Liverpool Lung Project biorepository. His main research focus is discovery and validation of biomarkers for early detection of lung can  cer and treatment stratification.


Dr Triantafillos (Lakis) Liloglou received his BSc (hons) in Biology from the Aristotelian University of Thessaloniki and his PhD in molecular oncology from the University of Crete Medical School. After his post-doctoral training at the University of Liverpool he became a group leader while joining the Liverpool Lung Project in 1998. Following a long career at the University of Liverpool, he is currently a Senior Lecturer and the MCh/MMed Programme Leader at Edge hill University. He is an expert committee member and reviewer in a number of funding committees and scientific journals. He has 155 publications in peer reviewed journals and a h-index 45.

His research focuses in genetic and epigenetic instability in cancers of the respiratory tract. Particular emphasis is given to the discovery and validation of biomarkers for clinical management (early detection and therapeutic stratification). In the last 5 years, he intensified his research around extracellular vesicles and non-coding RNAs with a view of utilising these in liquid biopsies to allow for lung cancer diagnosis prior to clinical manifestation of the disease.

This event is organised by the Respiratory Research Centre. The Respiratory Research Centre aims to combine the university’s academic strengths with regional clinical expertise to drive the development of local home-grown respiratory research. The Centre aims to support projects with clear benefits for patients through a blend of academic and clinical expertise.

For more information about the Respiratory Research Centre please visit  About the Centre – Respiratory Research Centre (

Contact details: [email protected]